DE60130562D1 - Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel - Google Patents

Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel

Info

Publication number
DE60130562D1
DE60130562D1 DE60130562T DE60130562T DE60130562D1 DE 60130562 D1 DE60130562 D1 DE 60130562D1 DE 60130562 T DE60130562 T DE 60130562T DE 60130562 T DE60130562 T DE 60130562T DE 60130562 D1 DE60130562 D1 DE 60130562D1
Authority
DE
Germany
Prior art keywords
hydrogen
group selected
antitumular
agents
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60130562T
Other languages
English (en)
Inventor
Antonio Longo
Maria Gabriella Brasca
Paolo Orsini
Gabriella Traquandi
Valeria Pittala
Anna Vulpetti
Mario Varasi
Paolo Pevarello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pfizer Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia SRL filed Critical Pfizer Italia SRL
Application granted granted Critical
Publication of DE60130562D1 publication Critical patent/DE60130562D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60130562T 2000-06-19 2001-06-13 Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel Expired - Lifetime DE60130562D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/597,274 US6335342B1 (en) 2000-06-19 2000-06-19 Azaindole derivatives, process for their preparation, and their use as antitumor agents
PCT/EP2001/006890 WO2001098299A1 (en) 2000-06-19 2001-06-13 Azaindole derivatives, process for their preparation, and their use as antitumor agents

Publications (1)

Publication Number Publication Date
DE60130562D1 true DE60130562D1 (de) 2007-10-31

Family

ID=24390825

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60130562T Expired - Lifetime DE60130562D1 (de) 2000-06-19 2001-06-13 Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel

Country Status (11)

Country Link
US (2) US6335342B1 (de)
EP (1) EP1309590B1 (de)
JP (1) JP2004501152A (de)
KR (1) KR20030010739A (de)
AT (1) ATE373656T1 (de)
AU (2) AU2001266079B2 (de)
CA (1) CA2411865A1 (de)
DE (1) DE60130562D1 (de)
MX (1) MXPA02012166A (de)
NZ (1) NZ523002A (de)
WO (1) WO2001098299A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
NZ525892A (en) * 2000-11-27 2004-11-26 Pharmacia Italia S Phenylacetamido- pyrazole derivatives their use as antitumor agents and preparation process thereof
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
AU2005269387A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN101027302B (zh) * 2004-07-27 2011-05-11 Sgx药物公司 吡咯并吡啶激酶调节剂
BRPI0513916A (pt) * 2004-07-27 2008-05-20 Sgx Pharmaceuticals Inc moduladores de pirrol-piridina cinase
ES2301066T3 (es) * 2004-10-14 2008-06-16 F. Hoffmann-La Roche Ag Nuevas azaindol-tiazolinonas como agentes anti-cancerosos.
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
FR2884821B1 (fr) 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
EP1881983B1 (de) * 2005-05-20 2012-01-11 Vertex Pharmaceuticals, Inc. Pyrrolopyridine als proteinkinasehemmer
FR2887881B1 (fr) * 2005-07-01 2009-10-09 Pierre Fabre Medicament Sa Inhibiteurs de proteines kinases
EP2251341A1 (de) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclische Januskinase-3-Inhibitoren
EP1910358A2 (de) * 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclische januskinase-3-inhibitoren
US20070149506A1 (en) * 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TWI468162B (zh) 2005-12-13 2015-01-11 英塞特公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
FR2907120B1 (fr) 2006-10-12 2013-01-11 Sanofi Aventis Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
US8148361B2 (en) * 2006-11-10 2012-04-03 Bristol-Myers Squibb Company Kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US8513270B2 (en) * 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
ES2546816T3 (es) 2007-02-27 2015-09-28 Nerviano Medical Sciences S.R.L. Isoquinolinpirrolopiridinonas activas como inhibidores de cinasa
EP1980561B1 (de) 2007-03-30 2013-10-09 Nerviano Medical Sciences S.R.L. Substituierte 1h-Pyrazolo[3,4-b]-pyridin-Derivate, die als Kinasehemmer aktiv sind
DE602008003055D1 (de) 2007-05-31 2010-12-02 Nerviano Medical Sciences Srl Zyklokondensierte Azaindole, die als Kinase-Hemmer wirken
EP2003129B1 (de) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-on und 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-on-Derivate
SG10201509887UA (en) 2007-06-13 2016-01-28 Incyte Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP2170830B1 (de) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZOSULFONAMID-VERBINDUNGEN ALS Raf-KINASE-MODULATOREN
RU2453536C2 (ru) * 2007-10-22 2012-06-20 Оркид Рисерч Лабораториз Лимитед Ингибиторы гистондезацетилазы
EP2070928A1 (de) * 2007-12-12 2009-06-17 NERVIANO MEDICAL SCIENCES S.r.l. Als Kinasehemmer wirkende 7-Azaindol-3-ylacrylamide
EP2265608A2 (de) * 2008-02-29 2010-12-29 Array Biopharma, Inc. Raf-hemmende verbindungen und anwendungsverfahren dafür
ES2602577T3 (es) * 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
EA025520B1 (ru) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
EP2266562A1 (de) * 2009-06-23 2010-12-29 Centre National de la Recherche Scientifique Verwendung von Indol-Derivaten zur Krebsbehandlung
WO2011028685A1 (en) * 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8486902B2 (en) 2009-10-09 2013-07-16 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
BR112012012156A2 (pt) 2009-11-06 2015-09-08 Plexxikon Inc compostos e métodos para modulação de cinase, e indicações para esta
JP5858434B2 (ja) * 2010-02-18 2016-02-10 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
MX347851B (es) 2010-03-10 2017-05-16 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
KR101851810B1 (ko) 2010-04-16 2018-04-26 에이씨 이뮨 에스.에이. 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 신규 화합물
EP2574168B9 (de) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topische formulierung für einen jak-hemmer
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TR201816421T4 (tr) 2011-02-07 2018-11-21 Plexxikon Inc Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
AU2012219395B2 (en) 2011-02-18 2017-05-25 Incyte Corporation mTOR/JAK inhibitor combination therapy
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
USRE48140E1 (en) * 2011-03-31 2020-08-04 Carna Biosciences, Inc. Furanone derivative
EP2717694A4 (de) * 2011-06-10 2014-11-12 Glaxosmithkline Intellectual Property Ltd Neuartige verbindungen
CA2839767A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
BR112015010663B1 (pt) 2012-11-15 2022-12-06 Incyte Holdings Corporation Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
EP2928864B1 (de) 2012-12-07 2020-01-15 Biokinesis Neue derivate von indol für die behandlung von krebs, virusinfektionen und lungenkrankheiten
FR3001219A1 (fr) * 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
CN105189509B (zh) 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
CN104119331B (zh) * 2013-04-26 2018-02-06 广东东阳光药业有限公司 烯基化合物及其使用方法和用途
WO2014193647A2 (en) * 2013-05-26 2014-12-04 Calitor Sciences, Llc Alkenyl compounds and methods of use
RS60469B1 (sr) 2013-08-07 2020-07-31 Incyte Corp Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
EP3096761A1 (de) 2014-01-24 2016-11-30 Confluence Life Sciences, Inc. Substituierte pyroolopyridine und pyrrolopyrazine zur behandlung von krebs oder entzündlichen erkrankungen
JP6569908B2 (ja) 2014-01-31 2019-09-04 カルナバイオサイエンス株式会社 抗がん剤組成物
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
EP3247353A4 (de) 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Heterocyclische itk-inhibitoren zur behandlung von entzündungen und krebs
EP3307724B1 (de) * 2015-06-12 2020-06-10 National University of Singapore (z)-2-(1h-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitril-derivate und ähnliche verbindungen mit lysosomhemmender und anti-mitotischer wirkung zur behandlung von hyperproliferativen erkrankungen
EP3795609B1 (de) 2015-07-01 2024-04-03 California Institute of Technology Kationische schleimsäurepolymerbasierte abgabesysteme
JP7130180B2 (ja) 2016-10-24 2022-09-05 ディアキュレイト 子宮内膜症の処置のためのインドールの新規誘導体
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5952355A (en) * 1993-11-17 1999-09-14 Kyowa Hakko Kogyo Co., Ltd. Propenone derivatives
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
US5977131A (en) * 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents

Also Published As

Publication number Publication date
WO2001098299A1 (en) 2001-12-27
JP2004501152A (ja) 2004-01-15
ATE373656T1 (de) 2007-10-15
EP1309590A1 (de) 2003-05-14
CA2411865A1 (en) 2001-12-27
US6486322B1 (en) 2002-11-26
AU6607901A (en) 2002-01-02
US20030004350A1 (en) 2003-01-02
AU2001266079B2 (en) 2006-08-24
MXPA02012166A (es) 2003-04-25
NZ523002A (en) 2004-09-24
KR20030010739A (ko) 2003-02-05
US6335342B1 (en) 2002-01-01
EP1309590B1 (de) 2007-09-19

Similar Documents

Publication Publication Date Title
DE60130562D1 (de) Azaindolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
DK1159279T3 (da) 4-Oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamider som antivirale midler
CY1117132T1 (el) Παραγωγο θειαζολιου
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
ATE208779T1 (de) Substituierte spiroheterocyclische 1h-3-aryl- pyrrolidin-2,4-dion-derivate, verfahren zu deren herstellung und deren verwendung als schädlingsbekämpfungsmittel
PL125789B1 (en) Process for preparing novel derivatives of quinazoline
MXPA04000407A (es) Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales.
MY131762A (en) Pharmaceutical compounds
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
ATE223925T1 (de) 2,2'-disubstituierte 1,1'-diphosphino-ferrocene und 1',2-disubstituierte 1-phosphino-ferrocene, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende übergangsmetallkomplexe
WO1999021848A3 (en) Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
ATE269329T1 (de) Neue basische derivate von benz(e)isoindol-1-onen und pyrrolo(3,4-c)chinolin-1-onen mit 5-ht3- antagonistischer aktivität, ihre herstellung und ihre therapeutische verwendung
ATE261441T1 (de) Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
ES2111086T3 (es) Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos.
EP0884318A4 (de) Kondensierte purinderivate
NZ291855A (en) Bridged azabicyclo-piperazin-1-yl-2-phenyl-butan-1-one derivatives as 5-ht1a antagonists
ATE170188T1 (de) 2'-desoxy-5-fluoruridin, pharmazeutisch anwendbare salze davon, verfahren zu ihrer herstellung und antitumormedikament
MY138045A (en) New benzo[b]pyrano[3,2-h]acridin-7-one cinnamate compounds, a process for their preparation and pharmaceutical compositions containing them
EP1724270A3 (de) Phenylacetamido-thiazole Verbindungen, Verfahren zu ihren Herstellung und ihre Anwendung als antitumor Mittel

Legal Events

Date Code Title Description
8332 No legal effect for de